sorafenib has been researched along with yttrium radioisotopes in 44 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (yttrium radioisotopes) | Trials (yttrium radioisotopes) | Recent Studies (post-2010) (yttrium radioisotopes) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,407 | 339 | 1,533 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.27) | 29.6817 |
| 2010's | 35 (79.55) | 24.3611 |
| 2020's | 8 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Palmer, D | 1 |
| Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; Rodríguez, M; Turnes, J; Varela, M | 1 |
| Merle, P; Mornex, F | 1 |
| Choi, BI; Kim, KW; Lee, JM | 1 |
| Han, KH; Kim, DY | 1 |
| Kim, DY; Kim, YH | 1 |
| Kim, BK; Kim, DY; Kim, EH; Kim, SU | 1 |
| Abecassis, M; Atassi, R; Baker, T; Ganger, D; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, M; Nayar, R; Salem, R; Vouche, M; Yaghmai, V | 1 |
| Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M | 1 |
| Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH | 1 |
| Abecassis, M; Al-Saden, P; Baker, T; Cotliar, J; Ganger, D; Habib, A; Karp, J; Koppe, S; Kulik, L; Lacouture, M; Lewandowski, RJ; Mulcahy, MF; Salem, R; Vouche, M | 1 |
| Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F | 1 |
| Shouval, D | 1 |
| Bruix, J; Forner, A; Gilabert, M; Raoul, JL | 1 |
| Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V | 1 |
| Boucher, E; Boudjema, K; Breton, M; Clement, B; Edeline, J; Garin, E; Icard, N; Laffont, S; Lenoir, L; Mesbah, H; Raoul, JL; Rohou, T; Rolland, Y; Sulpice, L | 1 |
| Chapiro, J; Duran, R; Geschwind, JF; Schernthaner, RE | 1 |
| Adhoute, X; Blanc, JF; Boucher, E; Boudjema, K; Campillo-Gimenez, B; Clément, B; Crouzet, L; Edeline, J; Garin, E; Guillygomarc'h, A; Lenoir, L; Pracht, M; Rohou, T; Rolland, Y | 1 |
| Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M | 1 |
| Abdel-Rahman, OM; Elsayed, Z | 1 |
| Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M | 1 |
| Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B | 1 |
| Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M | 1 |
| Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R | 1 |
| Friedman, T; Kishore, S; Madoff, DC | 1 |
| Eggert, T; Greten, TF | 1 |
| Chow, PK; Gandhi, M; Gebski, V | 1 |
| Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V | 1 |
| Hasegawa, K; Kokudo, N; Kokudo, T | 1 |
| Finn, RS; Llovet, JM | 1 |
| Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y | 1 |
| Chatellier, G; Dinut, A; Pereira, H; Vilgrain, V | 1 |
| Bae, SH; Bartlett, A; Cheow, PC; Choo, SP; Chotipanich, C; Chow, PKH; Cua, IHY; Gandhi, M; Gebski, V; Goh, ASW; Goh, BKP; Han, HS; Hung, CF; Jong, YW; Khasbazar, A; Khin, MW; Kim, YH; Kok, KYY; Law, CS; Lee, RC; Lekurwale, G; Lesmana, LA; Liang, PC; Liew, WM; Lim, K; Lo, RHG; Lobo, RR; Low, AS; Mak, KSW; Manuaba, TW; Ng, DCE; Ong, J; Peng, CY; Raj, A; Soo, KC; Tan, SB; Tay, KH; Teh, CSC; Thng, CH; Yoon, HK; Yoong, BK | 1 |
| Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G | 1 |
| Amini, N; Borbath, I; dʼAbadie, P; Goffette, P; Lhommel, R | 1 |
| Amthauer, H; Bargellini, I; Bartenstein, P; de Toni, EN; Gasbarrini, A; Klümpen, HJ; Malfertheiner, P; Pech, M; Peck-Radosavljevic, M; Popovič, P; Ricke, J; Rosmorduc, O; Sangro, B; Schott, E; Seidensticker, M; Verslype, C | 1 |
| Chatellier, G; Hawkins, NS; Palmer, DH; Pereira, H; Ross, PJ; Vilgrain, V | 1 |
| Canbay, A; Chatellier, G; Chow, PKH; Donghia, R; Gandhi, M; Guerra, V; Leandro, G; Malfertheiner, P; Pech, M; Pereira, H; Ricke, J; Venerito, M; Vilgrain, V | 1 |
| Brennan, VK; Colaone, F; Evans, R; Mullan, D; Muszbek, N; Remak, E; Ross, PJ; Shergill, S | 1 |
| Ang, C; Buckstein, M; Ferket, BS; Kim, E; Marqueen, KE; Mazumdar, M | 1 |
| Chatellier, G; Durand-Zaleski, I; Mimouni, M; Pereira, H; Vilgrain, V; Zarca, K | 1 |
| Agirrezabal, I; Brennan, VK; Chatellier, G; Colaone, F; Pereira, H; Shergill, S; Vilgrain, V | 1 |
| Amthauer, H; Bargellini, I; Bartenstein, P; Benckert, J; Berg, T; Gasbarrini, A; Gebauer, B; Iezzi, R; Klümpen, HJ; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Philipp, A; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Sengel, C; van Delden, O; Vandecaveye, V; Verslype, C; Zech, CJ | 1 |
| Aikimbaev, K; Balli, HT; Burak, IG; Pehlivan, UA; Piskin, FC; Sozutok, S | 1 |
10 review(s) available for sorafenib and yttrium radioisotopes
| Article | Year |
|---|---|
Contemporary management of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Yttrium Radioisotopes | 2008 |
[Nonsurgical management of hepatocellular carcinoma].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Radiotherapy, Conformal; Sorafenib; Yttrium Radioisotopes | 2010 |
Assessment of the treatment response of HCC.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Contrast Media; Ethanol; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Drug Carriers; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Yttrium Radioisotopes | 2013 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Diffusion of Innovation; Embolization, Therapeutic; Female; Forecasting; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Niacinamide; Patient Selection; Phenylurea Compounds; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Yttrium Radioisotopes | 2016 |
Update on Embolization Therapies for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2017 |
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proton Therapy; Radiosurgery; Radiotherapy; Sorafenib; Survival Rate; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2017 |
NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2020 |
10 trial(s) available for sorafenib and yttrium radioisotopes
| Article | Year |
|---|---|
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Technetium Tc 99m Aggregated Albumin; World Health Organization; Yttrium Radioisotopes | 2013 |
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes | 2014 |
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rejection; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Radiation Dosage; Sorafenib; Yttrium Radioisotopes | 2014 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Platelet-Derived Growth Factor; Prospective Studies; Radiopharmaceuticals; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2017 |
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Sorafenib; Yttrium Radioisotopes | 2018 |
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Palliative Care; Research Design; Sorafenib; Yttrium Radioisotopes | 2019 |
Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Function Tests; Liver Neoplasms; Male; Microspheres; Patient Selection; Prognosis; Sorafenib; Survival Rate; Tumor Burden; Yttrium Radioisotopes | 2020 |
Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Microspheres; Quality of Life; Sorafenib; Yttrium Radioisotopes | 2021 |
24 other study(ies) available for sorafenib and yttrium radioisotopes
| Article | Year |
|---|---|
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2012 |
Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Sorafenib; Yttrium Radioisotopes | 2013 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cause of Death; Embolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2015 |
The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female; Glass; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiometry; Retrospective Studies; Sorafenib; Thrombosis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2015 |
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Sorafenib; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Logistic Models; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Yttrium Radioisotopes | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Sorafenib; Thrombosis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Microspheres; Multicenter Studies as Topic; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2018 |
Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Male; Radiopharmaceuticals; Sorafenib; Technetium Tc 99m Aggregated Albumin; Yttrium Radioisotopes | 2019 |
Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Health Care Costs; Humans; Liver; Liver Neoplasms; Microspheres; Patient Selection; Quality of Life; Quality-Adjusted Life Years; Sorafenib; Survival Analysis; Tumor Burden; United Kingdom; Yttrium Radioisotopes | 2021 |
Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Medicare; Quality of Life; Sorafenib; United States; Yttrium Radioisotopes | 2021 |
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Quality of Life; Sorafenib; Yttrium Radioisotopes | 2022 |
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2022 |
Reduction of Hepatopulmonary and Intrahepatic Shunts after Treatment with Sorafenib in Hepatocellular Carcinoma Patients.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2022 |